ADC Control Human IgG1-Deruxtecan (DAR 4)
The ADC Control Human IgG1-Deruxtecan (DAR 4) is a humanized monoclonal antibody conjugated with Deruxtecan, a potent topoisomerase I inhibitor. This conjugate acts as an isotype control in antibody-drug conjugate (ADC) research, helping assess nonspecific effects in experimental setups.
Key Features:
- Isotype Control: Uses a human IgG1 antibody that does not bind to specific antigens, ensuring that any effects are due to the drug conjugate.
- Drug-Linker Conjugate: Combines Deruxtecan, a topoisomerase I inhibitor, with the antibody via a cleavable linker.
- Drug-to-Antibody Ratio (DAR): Features a DAR of 4, meaning each antibody has an average of 4 drug molecules attached.
Applications:
- Control in ADC Studies: Acts as a negative control to distinguish between specific and nonspecific effects in ADC experiments.
- Mechanistic Research: Helps study the pharmacokinetics and pharmacodynamics of ADCs.
- Method Development: Supports the development of methods for ADC characterization.
Handling and Storage:
- Storage: Store at -20°C, protected from light and moisture.
- Handling: Use standard laboratory precautions when handling this reagent.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.